SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Stein JP,Lieskovsky G,Cote R, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol. 2001; 19: 666675.
  • 2
    Sternberg CN,Yagoda A,Scher HI, et al. Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium. J Urol. 1985; 133: 403407.
  • 3
    Galsky MD,Herr HW,Bajorin DF. The integration of chemotherapy and surgery for bladder cancer. J Natl Compr Cancer Netw. 2005; 3: 4551.
  • 4
    Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data. Eur Urol. 2005; 48: 202205.
  • 5
    Herr HW,Dotan Z,Donat SM,Bajorin DF. Defining optimal therapy for muscle invasive bladder cancer. J Urol. 2007; 177: 437443.
  • 6
    von der Maase H,Hansen SW,Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol. 2000; 18: 30683077.
  • 7
    von der Maase H,Sengelov L,Roberts JT, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol. 2005; 23: 46024608.
  • 8
    Dash A,Pettus JAIV,Herr HW, et al. A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experience. Cancer. 2008; 113: 24712477.
  • 9
    David KA,Milowsky MI,Ritchey J,Carroll PR,Nanus DM. Low incidence of perioperative chemotherapy for stage III bladder cancer 1998 to 2003: a report from the National Cancer Data Base. J Urol. 2007; 178: 451454.
  • 10
    Maitland ML,DiRienzo A,Ratain MJ. Interpreting disparate responses to cancer therapy: the role of human population genetics. J Clin Oncol. 2006; 24: 21512157.
  • 11
    Bellmunt J,Paz-Ares L,Cuello M, et al. Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy. Ann Oncol. 2007; 18: 522528.
  • 12
    Ceppi P,Volante M,Novello S, et al. ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine. Ann Oncol. 2006; 17: 18181825.
  • 13
    Lord RV,Brabender J,Gandara D, et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res. 2002; 8: 22862291.
  • 14
    Olaussen KA,Dunant A,Fouret P, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med. 2006; 355: 983991.
  • 15
    Sonpavde G,Ross R,Powles T, et al. Novel agents for muscle-invasive and advanced urothelial cancer. BJU Int. 2008; 101: 937943.